DATA UP TO 52 WEEKS
is available

Clinical, histologic, and
endoscopic endpoints1,2

DUPIXENT was studied across
multiple endpoints.

VIEW THE RESULTS

Demonstrated
safety profile1

The safety of DUPIXENT was
evaluated
at Week 24 and up
to 52 weeks in the
multipart,
phase 3 clinical trial.

EXPLORE THE DATA

DUPIXENT MyWay® is a patient support
program
that can help
enable access to
DUPIXENT
and offers financial assistance
for
eligible
patients, one-on-one nursing
support, and more.

DUPIXENT MyWay
ENROLLMENT FORMS

English Enrollment Form
Spanish Enrollment Form